Jada Bascom Foundation
All conditions

Autoimmune conditions

Stiff-person spectrum disorder

Also called: SPSD · SPS · PERM · GAD65-antibody stiff-person syndrome · GlyR-antibody SPS · Stiff-person syndrome · Stiff-man syndrome · Progressive encephalomyelitis with rigidity and myoclonus

What a donor has to do with this

A transplant is not a standard part of treating this condition. It is used rarely, in particular situations, and most people diagnosed with it will not have one.

This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.

This page is not written out in full yet

We have not written this condition out in full yet. What is on this page — how a donor fits in, who it affects, and the sources behind that — is researched and linked, but the plain-English explanation of the condition itself is still to come.

What the evidence says

Who it affects
In the Johns Hopkins cohort observed from 1997–2022 and published in 2024, stiff-person spectrum disorder began at a mean age of about 43, diagnosis followed a median 36 months later, and nearly 76% of patients were female.
Treatments other than a transplant
Diazepam or other benzodiazepines and baclofen are principal symptomatic antispasmodic therapies; rehabilitation and trigger management are essential.; IVIg has the best-established immunotherapy evidence; plasma exchange, rituximab, mycophenolate, or other immunosuppression are selected case by case.; No drug or HCT approach is established as a universal cure across the heterogeneous spectrum.
If a transplant is used, the cells come from
autologous mobilized peripheral-blood stem cells (dominant contemporary source); bone marrow: not reported in the opened disease-specific sources; cord blood: not reported in the opened disease-specific sources
How often the donor was unrelated
Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.

Where this gets complicated

Evidence remains Class IV and cohorts are small; response is not uniform and selection by antibody/phenotype is unsettled.; The spectrum includes classic SPS, variants, and PERM with different biology and urgency; these should not be assumed equivalent.; IVIg and symptomatic therapy have broader established use, while transplant adds infertility, infection, secondary-autoimmunity, and conditioning risks.

Written for transplant clinicians, not for patients. We quote it so you can see what the guidance actually says:
“for a subset of people with SPSD, autologous nonmyeloablative HSCT improves outcomes.”

It describes what teams consider in general. It cannot say what applies to any one person. Read the source.

Registries need people

An unrelated donor is not a usual part of treating this condition. Registering still matters, for the many conditions where it is.

Joining a registry is a cheek swab and a short health form. You are not matched to a condition — you are matched to a person, and it could be someone with any of the conditions in this library. You are contacted only if you turn out to be a possible match for someone, and you can ask questions and decline before anything else happens.

Find your registry

Related conditions

Others in autoimmune conditions. They are genuinely different diseases with different treatments — the group name is not a diagnosis.

Where this came from